Key facts
- Manina Medtech’s last known valuation is $12.0M (Sep 2023).
- It has raised $2.5M; the latest was Later Stage VC ($550K) in Feb 2026.
- Notable investors include Consorci de la Zona Franca, ACCIÓ, Barcelona Activa, Biocat, CIMTI — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Manina Medtech
- ·The full record, as it builds
Funding rounds
No funding rounds for Manina Medtech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Manina Medtech
Developer of a medical device designed for improving embryo transfer success in assisted reproduction. The company's device helps to assess uterine readiness through non-invasive biomarker analysis, offering data on endometrial conditions, enabling fertility specialists to optimize embryo implantation timing, enhance pregnancy rates, and reduce treatment cycles by providing artificial intelligence-driven recommendations without requiring biopsies or invasive procedures.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 10
- Website
- maninamedtech.com/
- Ownership
- Privately Held (backing)
Manina Medtech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Manina Medtech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Manina Medtech in its N-PORT filings yet. We sweep new filings monthly.